MetaVia Inc. — Form 8-K
Filed November 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
MetaVia (Nasdaq: MTVA, ~$3M market cap) announced interim Phase 1 Part 3B results for DA-1726, a GLP-1/glucagon dual agonist: 68.1% placebo-adjusted liver fat reduction, 13.5% weight loss, and 0.24 pp HbA1c reduction at 16 weeks in 15 obese subjects with no new GI adverse events after week 9. The company appointed Sarah Browne, M.D. as Chief Medical Officer and plans a 48-week Phase 2 study in up to 150 subjects with MetALD/ALD starting H2 2027. Cash position was $8.8M as of September 30, 2026, with 9-month net loss of $13.8M ($2.36 per share, 5.8M weighted average shares).
Why this rating
Strong early efficacy in a $3M company de-risks a new indication (MetALD, 10.7M patient US market, zero approvals). Phase 2 start is 12–18 months away; cash runway is tight, requiring financing. Material for company trajectory but execution risk remains high.
Tradability signal
NO TRADE
No trade: only ~$57k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $1.41 | +10 min · unknown $1.37 ▼ 2.84% | +30 min · unknown $1.34 ▼ 4.96% | +1 hr · unknown $1.26 ▼ 10.28% | +4 hrs · unknown $1.36 ▼ 3.55% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.